Allogene Therapeutics Inc
NASDAQ:ALLO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
US |
Intrinsic Value
The intrinsic value of Allogene Therapeutics Inc (ALLO) under the Base Case is 1.63 USD per share.
Compared with the current market price of 1.34 USD, the stock appears
Undervalued by 18% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Allogene Therapeutics Does
Allogene Therapeutics is a biotechnology company that develops off-the-shelf cell therapies, mainly allogeneic CAR-T treatments for cancer. Instead of making a custom therapy from each patient’s own cells, it works with donor cells that can be prepared in advance and stored until needed. Its goal is to make advanced cancer treatment easier to deliver and more widely available.
- Headquarters
- United States of America US
- Employees
- 150
- IPO date
- Oct 11, 2018
Revenue & Expenses Breakdown
Allogene Therapeutics Inc
Earnings Waterfall
Allogene Therapeutics Inc
The intrinsic value for Allogene Therapeutics Inc (ALLO) under the Base Case is 1.63 USD.
Compared with the current market price of 1.34 USD, the stock appears Undervalued by 18% .